
Abeona Therapeutics Inc. (ABEO) Stock Ticker
ABEO right now
Market factors today
Unlock the full ABEO picture
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
ABEO stock facts
| Ticker symbol | ABEO |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $307.8M |
| CEO | Vishwas Seshadri |
| Employees | 226 |
| Headquarters | Cleveland, OH, US |
| IPO date | 1980-09-19 |
| Website | www.abeonatherapeutics.com |
What you can see for ABEO on Tickr
Live ABEO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ABEO report.
Rankings
FAQ
What is the ticker symbol for Abeona Therapeutics Inc.?
The ticker symbol for Abeona Therapeutics Inc. is ABEO, listed on the NASDAQ Capital Market.
What is ABEO?
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also…